Gout flare in the hand of an elderly person Researchers evaluated the efficacy and safety of anakinra for the treatment of acute gout flares. Undergoing 5 days of therapy with the IL-1 receptor ...

Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares ...

Management of a patient allergic to allopurinol can be considered a therapeutic challenge. This article highlights the diversity of medications that can be used to manage hyperuricemia during this ...

Atom’s focus on chronic and acute gout aims to combat a growing worldwide gout threat with few safe and effective existing treatments for patients. Lingdolinurad (ABP-671), a new URAT1 inhibitor, has ...

About half of people with gout don't have treatments that work. Meet the new gout drugs racing through trials to reach them.

Once considered a disease exclusive to the wealthy, gout has doubled in prevalence over the last few decades due to its ...

NEW YORK CITY — Urate, the culprit of gout, affects the vasculature in multiple ways that can raise cardiovascular risk (CV) in an individual with gout, and following guidelines for gout treatment, ...

The European Medicines Agency (EMA) on Thursday issued a guideline setting its expectations for the clinical development of new urate-lowering therapies (ULT) and anti-inflammatory drugs to treat gout ...

Over the years, gout has grown in clinical complexity. We see many more cases with iatrogenic factors, multiple comorbidities, advanced age and treatment-refractory hyperuricemia and arthritis (Table ...

Patients with gout flares are at heightened risk of acute MI or stroke—above and beyond their already increased cardiovascular risk—over the following 4 to 6 months, an observational study suggests.

Scientific Workshop reveal significant gaps in the diagnosis and treatment of gout among people with chronic kidney disease (CKD), prompting experts to call for earlier diagnosis, personalized ...

HANGZHOU, China, June 15, 2026--(BUSINESS WIRE)--Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today Roy J. Wu, ...